About Us
About Us
About CGeneTech

CGeneTech(Suzhou,China) Co., Ltd.is a biotechnology company in the commercialization stage, with its core product, Class 1 innovative drug Shenggliptin, on the market. The company was founded in Suzhou Industrial Park in 2010, with a core team witdecades of experience in the entire lifecycle of international drugs, dedicated to the research and development and industrialization of high-quality and differentiated small molecule innovative drugs. With an integrated drug research and development technology platform and a diversified business perspective, the company has built a rich pipeline of innovative drugs covering hypoglycemic, anticancer, and autoimmune diseases.
In recent years, the new hypoglycemic drug DPP-4 inhibitors have become increasingly popular in China, and are praised by clinical doctors as the "smartest hypoglycemic drugs". The new generation of highly selective DPP-4 inhibitor Shenggliptin independently developed by the company in this field has been selected for the "Major New Drug Creation" special projects of the 12th and 13th Five Year Plans of the country. Currently, it has submitted an NDA (New Drug Listing Application) to the National Drug Administration and has been accepted. The results of the Phase 3 clinical trial showed that low doses can reach the predetermined trial endpoint, while the high-dose group can also demonstrate the safety of the drug well. The therapeutic effect of "half the dose, twice the effort" makes it expected to become the best hypoglycemic drug in the class. At the same time, the company has also carried out a comprehensive layout of oral drugs and derivative diseases around the global mainstream target of diabetes, in which the world's first SGLT-2/DPP-4 dual target inhibitor has been approved for clinical use to better treat diabetes and its derivative diseases.


Four anticancer drugs under research have entered clinical practice, and the FGFR/VEGFR dual target inhibitor CGT-6321 has been tested in phase I clinical trials in advanced solid tumors, which is expected to become a potential first in class drug; CDK4/6 inhibitor CGT-1967, differentially selected for the treatment of acute myeloid leukemia (AML) patients, to explore the unmet clinical needs in this field; CXCR4 antagonists are receiving increasing attention globally, and CGT-1881 targeting this target is used in treatment fields such as hematopoietic stem cell mobilization. It is the only original small molecule oral CXCR4 antagonist in China, making administration more convenient; The new generation of ALK inhibitor CGT-9475 is expected to address several major clinical pain points in the treatment of lung cancer, including drug resistance and brain metastasis. The latter two projects have both obtained clinical licenses from the US FDA, marking a solid step towards the company's innovative drug market. In addition, the first domestic imitation of the treatment of rare disease multiple sclerosis, Terifluoramide tablets, has been launched and sold.
In the future, the company will be guided by unmet clinical needs and develop innovative drugs with high accessibility and better efficacy to benefit patients worldwide.




Developing innovative medicines with high patient access and improved efficacy to benefit patients worldwide



Virtue, innovation, truthfulness, and worldliness

Contact Us

Add:Room 101, Bld C11, 218 Xinghu Rd,Suzhou industrial Park,China, 215123

Tel: +86-512-62956960(Recruitment)


Copyright © 2022  CGeneTech (Suzhou, China) Co., Ltd.  All rights reserved.  苏ICP备2022006552号-1  Powered by 300.cn  SEO